Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Orphan Medical launches improved form of busulfan in U.S.

Feb. 24, 1999

U.S. patent extends coverage for Immune Response's TCR vaccine technology

Feb. 24, 1999

Immunomedics and NCI to study new class of anticancer agents

Feb. 24, 1999

NeoPharm and Pharmacia & Upjohn reach licensing agreement for liposomal cancer formulations

Feb. 24, 1999

Activity of novel deoxyadenosine analogue investigated against human colon tumors

Feb. 23, 1999

Antiproliferative agents from Warner-Lambert act by inhibiting MEK kinase

Feb. 23, 1999

U.S. patent covers fundamental basis of Prolifix's R&D program

Feb. 23, 1999

FDA permits initiation of GlycoDesign's phase I/II study of GD0039 as chemoprotective agent

Feb. 22, 1999

Liposome initiates phase I clinical trial of TLC-ELL-12

Feb. 22, 1999

FDA accepts NDA filing for Evacet

Feb. 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...